Navigation Links
Gene-Transfer Proves Safe for Vision Problem
Date:9/12/2008

Volunteers with rare eye disease regained partial sight with experimental therapy

FRIDAY, Sept. 12 (HealthDay News) -- Three people with a rare, incurable form of hereditary blindness regained some sight after receiving experimental gene therapy, a new report says.

The patients, all in their early 20s, have Leber congenital amaurosis type 2 (LCA2), a disease in which photoreceptor cells cannot respond to light, because a gene called RPE65 does not properly produce a protein necessary for healthy vision.

In the study, published online in Human Gene Therapy, researchers at the University of Florida used an adeno-associated virus. an apparently harmless virus that already exists in most people. to deliver RPE65 to a small area of the retina.

The subjects said the vision in their treated eyes was slightly improved in dim lighting conditions.

"The patients report seeing brighter areas and perhaps some images, but basically the message is that this treatment is fully safe," William W. Hauswirth, a professor of ophthalmology and member of the university's Powell Gene Therapy Center, said in a news release issued by the university.

No ill effects, other than routine post-surgical soreness, were reported.

"The study has partially restored vision in three young adults, and it demonstrates that gene therapy can be effective in treating human vision disease," Dr. Paul A. Sieving, director of the National Eye Institute, which supported the experiment, said in the same news release. "Many human diseases are inherited in families and result from mutations in single genes. These genetic conditions are particularly suited to potential treatment by gene therapy. This trial to treat vision loss from the condition of Leber congenital amaurosis is an important demonstration of proof of principle and shows that we are on the right track. We can now invest in further work to refine, and ultimately to expand, genetic treatment approaches."

A detailed examination of the therapy's effectiveness in the treated portion of the eye was expected to be published in an upcoming issue of the Proceedings of the National Academy of Sciences.

LCA2 affects about 2,000 people in the United States and is one of several incurable forms of blindness collectively known as retinitis pigmentosa, which in turn affects about 200,000 Americans.

More information

The Prevent Blindness America has more about retinitis pigmentosa .



-- Kevin McKeever



SOURCE: University of Florida, news release, September 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Music Therapy Improves Well-Being of Very Ill Patients
2. Safety study indicates gene therapy for blindness improves vision
3. New study finds that add-on therapy improves depressive symptoms in bipolar disorder
4. FDA approves first drug for Huntingtons disease
5. Light Stretching Improves Range of Joint Motion
6. The California Board of Registered Nursing Approves Affiliations for Nursing Program in Glendale, California
7. Free White Paper: Hospital Tests Patient Lift Technologies; Improves Quality of Care
8. Overcoming inhibitors of cell death improves cancer therapy efficacy
9. New study shows calcium significantly improves childrens bone health
10. Madrid Hospital Improves Employee Safety With Ekahau Wi-Fi RTLS
11. Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: